GlassScriptPhysician profile
Mallory J Smith
NPI 1720561160
$1,470.08
in general payments reported to CMS, 2019-2025
25 companies · $504 in 2025
The $504 reported for 2025 was more than what 86% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $400 · 2023: $190 · 2024: $259 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $188.00 | 2021-2025 | Slynd |
| Sage Therapeutics, LLC | $147.65 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $124.85 | 2024 | Veozah |
| Mylan Pharmaceuticals INC. | $124.65 | 2021-2022 | |
| Glaxosmithkline, LLC. | $122.55 | 2022 | |
| Biogen, INC. | $119.82 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $75.42 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.87 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $55.15 | 2021-2022 | |
| Agile Therapeutics, INC. | $52.63 | 2021-2022 | |
| Axsome Therapeutics, INC. | $48.42 | 2023 | Auvelity |
| Millicent US INC | $44.29 | 2025 | Intrarosa, Femlyv |
| Sumitomo Pharma America, INC. | $43.61 | 2023-2025 | Myfembree, Gemtesa |
| Agios Pharmaceuticals, INC. | $40.24 | 2024-2025 | Pyrukynd |
| Supernus Pharmaceuticals, INC. | $36.72 | 2025 | Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $35.00 | 2024-2025 | Nexplanon |
| Corium, LLC | $23.02 | 2022 | |
| Baxter Healthcare | $21.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.14 | 2023 | Xifaxan, Trulance |
| Novo Nordisk INC | $19.09 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $15.59 | 2023 | Trintellix |
| Shield Therapeutics INC | $14.21 | 2023 | Accrufer |
| Pfizer INC. | $13.93 | 2024 | |
| Lilly USA, LLC | $13.54 | 2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.